Okrelizumab (Ocrelizumab)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Antineoplastic agents - monoclonal antibodies

Included in the formulation
  • Ocrewus®
    concentrate d / infusion 
    Hoffmann-La Roche Ltd.     Switzerland
    • АТХ:

    L.04.A.A.36   Okrelizumab

    Pharmacodynamics:

    Monoclonal antibody with immunosuppressive action, binds by receptors CD20, located on the surface of B-lymphocytes, which leads to their destruction by antibody-dependent cytolysis and lysis mediated by the complement system. Reducing the number of pre-B and mature forms of B-lymphocytes suppresses humoral immunity.

    Pharmacokinetics:

    After intravenous administration, it is exposed to tissue catabolism to amino acids. Penetrates through the placental barrier, is found in breast milk.

    The half-life is 26 days. Elimination by the kidneys.

    Indications:

    It is used to treat primary-progressive and recurrent forms of multiple sclerosis.

    ICD-10

    VI.G35-G37.G35   Multiple sclerosis

    Contraindications:

    Age under 18, pregnancy and lactation, hepatitis B, acute infectious diseases, individual intolerance.

    Carefully:

    Heart failure, age over 65 years, hepatic and renal failure of severe and moderate severity, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - category is not defined. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Intravenously drip 300 mg, followed by infusion in the same dosage after 14 days. Repeated infusions - every 6 months for 600 mg.

    The highest daily dose: 600 mg.

    The highest single dose: 600 mg.

    Side effects:

    Central and peripheral nervous system: headache, dizziness, drowsiness, irritability, depression.

    Respiratory system: cough, sinusitis, bronchitis.

    Hemopoietic system: neutropenia.

    The cardiovascular system: tachycardia.

    Digestive system: nausea, loss or weight gain.

    Musculoskeletal system: pain in the back, cramps.

    Dermatological reactions: a rash, hives, herpes.

    Sense organs: decreased visual acuity, conjunctivitis.

    Infusion and allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic.

    Interaction:

    When used simultaneously with glucocorticoids and immunosuppressants, the risk of developing immunosuppression increases.

    Special instructions:

    Before intravenous administration, it is recommended that premedisolone be premedicated.

    Persons of reproductive age during the treatment period and within 6 months after the end of it are recommended to use reliable methods of contraception.

    During the reception of ocrelizumab and within 3 months after treatment, vaccination is not recommended.

    When taking the drug is not recommended driving and working with moving machinery.

    Instructions
    Up